PubRank

Louis M Staudt

Author PubWeight™ 366.67‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002 24.07
2 Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2003 13.92
3 Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004 12.20
4 Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010 8.78
5 Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010 8.74
6 A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006 8.11
7 A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003 7.57
8 Oncogenically active MYD88 mutations in human lymphoma. Nature 2010 7.34
9 Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007 7.10
10 XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 2004 6.72
11 Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008 6.52
12 IRF4 addiction in multiple myeloma. Nature 2008 6.27
13 Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002 6.27
14 The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003 6.11
15 Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006 6.10
16 Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003 6.06
17 Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008 5.90
18 Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 2004 5.10
19 Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013 4.96
20 Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005 4.84
21 Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012 4.33
22 A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009 3.87
23 Aggressive lymphomas. N Engl J Med 2010 3.86
24 Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci U S A 2002 3.85
25 Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012 3.59
26 Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004 3.55
27 A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev 2006 3.49
28 Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 2006 3.41
29 MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011 3.22
30 Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009 3.17
31 ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003 3.16
32 Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005 3.12
33 JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013 3.07
34 Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 2007 3.00
35 Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012 3.00
36 Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol 2004 2.90
37 ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004 2.79
38 The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 2010 2.71
39 High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A 2014 2.50
40 MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010 2.49
41 Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation. Cell 2007 2.46
42 Pathogenesis of human B cell lymphomas. Annu Rev Immunol 2012 2.44
43 Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 2010 2.43
44 Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002 2.37
45 Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol 2004 2.35
46 Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013 2.31
47 Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med 2013 2.31
48 Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2010 2.30
49 BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 2004 2.20
50 Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005 2.19
51 Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004 2.13
52 Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 2006 2.10
53 Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell 2013 2.06
54 BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006 2.02
55 Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008 2.00
56 Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008 1.95
57 Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med 2007 1.94
58 Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival. Nature 2008 1.91
59 Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2013 1.91
60 Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2009 1.90
61 Malignant pirates of the immune system. Nat Immunol 2011 1.87
62 Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 2009 1.83
63 A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 2010 1.82
64 TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov 2013 1.81
65 Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol 2007 1.80
66 SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009 1.79
67 Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood 2010 1.76
68 Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014 1.71
69 Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Discov 2014 1.70
70 Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med 2012 1.69
71 MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood 2003 1.69
72 The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002 1.68
73 A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood 2012 1.68
74 BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res 2011 1.67
75 Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 2014 1.66
76 IRF4: Immunity. Malignancy! Therapy? Clin Cancer Res 2009 1.61
77 Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Mol Cell Biol 2003 1.61
78 Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 2007 1.60
79 Characterization of early stages of human B cell development by gene expression profiling. J Immunol 2007 1.60
80 Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev 2012 1.60
81 Janus kinase deregulation in leukemia and lymphoma. Immunity 2012 1.52
82 The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 2008 1.50
83 Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004 1.48
84 Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells. Mol Cancer 2006 1.48
85 Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood 2009 1.46
86 Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. Leuk Lymphoma 2009 1.46
87 Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell 2012 1.43
88 Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen. Proc Natl Acad Sci U S A 2008 1.42
89 Repression of BCL-6 is required for the formation of human memory B cells in vitro. J Exp Med 2007 1.41
90 Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007 1.39
91 Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci U S A 2006 1.35
92 Active NF-kappaB signalling is a prerequisite for influenza virus infection. J Gen Virol 2004 1.35
93 Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma 2003 1.33
94 Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood 2010 1.30
95 Analysis of gamma c-family cytokine target genes. Identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. J Biol Chem 2002 1.28
96 Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol 2007 1.28
97 Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum Mol Genet 2004 1.27
98 Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood 2009 1.21
99 Congenital B cell lymphocytosis explained by novel germline CARD11 mutations. J Exp Med 2012 1.19
100 Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood 2005 1.19
101 EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 2013 1.17
102 Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica 2011 1.16
103 c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells. J Virol 2009 1.14
104 Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med 2014 1.12
105 Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. Haematologica 2008 1.11
106 Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood 2005 1.11
107 Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood 2012 1.11
108 C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma. Int J Cancer 2007 1.11
109 Molecular diagnosis of lymphoid malignancies by gene expression profiling. Curr Opin Hematol 2002 1.10
110 Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 2006 1.10
111 Two newly characterized germinal center B-cell-associated genes, GCET1 and GCET2, have differential expression in normal and neoplastic B cells. Am J Pathol 2003 1.08
112 Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood 2007 1.06
113 The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kappaB signal transduction pathway. Oncogene 2002 1.06
114 Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin. J Cell Sci 2009 1.05
115 Toll-like receptor signaling. Cold Spring Harb Perspect Biol 2013 1.05
116 Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood 2012 1.03
117 MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. Blood 2011 1.02
118 A cell-based assay for IkappaBalpha stabilization using a two-color dual luciferase-based sensor. Assay Drug Dev Technol 2007 1.01
119 Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. Clin Cancer Res 2011 1.00
120 Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice. Cancer Res 2005 0.99
121 Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood 2013 0.96
122 Inhibitors of the NF-kappaB activation pathway from Cryptocarya rugulosa. J Nat Prod 2009 0.95
123 MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood 2004 0.95
124 Dendritic cell fate is determined by BCL11A. Proc Natl Acad Sci U S A 2014 0.94
125 Related F-box proteins control cell death in Caenorhabditis elegans and human lymphoma. Proc Natl Acad Sci U S A 2013 0.93
126 Distinct gene expression profiles in different B-cell compartments in human peripheral lymphoid organs. BMC Immunol 2004 0.93
127 Clinical translation of gene expression profiling in lymphomas and leukemias. Semin Oncol 2002 0.92
128 Transcription factor Runx2 controls the development and migration of plasmacytoid dendritic cells. J Exp Med 2013 0.92
129 CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. Haematologica 2009 0.92
130 Identification of FoxM1/Bub1b signaling pathway as a required component for growth and survival of rhabdomyosarcoma. Cancer Res 2012 0.89
131 Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood 2012 0.88
132 Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. Genes Chromosomes Cancer 2007 0.87
133 Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput screens of NFkappaB activation. Bioorg Med Chem Lett 2007 0.83
134 BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we? Blood 2007 0.81
135 Towards molecular diagnosis and targeted therapy of lymphoid malignancies. Semin Hematol 2003 0.81
136 Molecular and cytological features of the mouse B-cell lymphoma line iMycEmu-1. Mol Cancer 2005 0.80
137 Protein ubiquitination in lymphoid malignancies. Immunol Rev 2015 0.80
138 Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. Int J Mol Epidemiol Genet 2011 0.79
139 Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research. Clin Adv Hematol Oncol 2003 0.79
140 Transformation of late passage insulin-like growth factor-I receptor null mouse embryo fibroblasts by SV40 T antigen. Cancer Res 2006 0.79
141 A new "brew" of MALT1 inhibitors. Cancer Cell 2012 0.78
142 High-throughput RNA sequencing in B-cell lymphomas. Methods Mol Biol 2013 0.77
143 The case of the missing c-Myc. Nat Immunol 2012 0.77
144 Multiplexing high-content flow (HCF) and quantitative high-throughput screening (qHTS) to identify compounds capable of decreasing cell viability, activating caspase 3/7, expressing annexin V, and changing mitochondrial membrane integrity. Curr Protoc Chem Biol 2013 0.77
145 Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. Am J Surg Pathol 2015 0.77
146 Cancer: negative feedback for B cells. Nature 2004 0.76
147 Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma. Leuk Lymphoma 2013 0.76
148 The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma. Leuk Lymphoma 2007 0.75
149 Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. Int J Cancer 2013 0.75